All
FDA Approves Tibsovo for Frontline IDH1-Mutant Acute Myeloid Leukemia
May 2nd 2019The FDA has approved a supplemental new drug application for Tibsovo as a single agent for the first-line treatment of adult patients with IDH1-mutant acute myeloid leukemia who are 75 years and older or are ineligible to receive intensive chemotherapy.
Survey Shows Split Between Blood Cancer Detection: Symptom Evaluation vs. Incidental Finding
April 30th 2019Only half of patients reported their blood cancer was detected while visiting a doctor after experiencing symptoms versus detection during a routine medical test or exam or while under the care of a doctor for another health condition.
Risk for Disease Progression Changes Over Time in CLL, Depending on Somatic Mutations
April 30th 2019Risk for disease progression among patients with chronic lymphocytic leukemia over time differed between those with mutated or unmutated disease, showing that gene somatic hypermutation plays a role throughout the disease course.